The PD-L1/PD-1 signaling axis is a pivotal regulator of T-cell activity and a key mechanism by which tumors evade immune surveillance. Inhibiting this pathway has resulted in significant anti-tumor responses, establishing immune checkpoint blockade (ICB) as a crucial component of modern cancer therapy. However, many patients with high PD-L1 expression do not respond to PD-1/PD-L1 blockade, underscoring the necessity for a deeper investigation into the mechanisms underlying this resistance. Recent studies have identified DRG2 as a critical modulator of anti-PD-1 therapeutic efficacy. While DRG2 depletion enhances IFN-γ signaling and increases the overall PD-L1 levels, it disrupts the recycling of endosomal PD-L1, resulting in reduced surface expression and impaired PD-1 interaction, ultimately compromising therapeutic outcomes. Furthermore, TRAPPC4, HIP1R, and CMTM6 help stabilize PD-L1 by preventing lysosome degradation. When depleted, these proteins have been shown to boost the body’s immune response against tumors. Research into the complex regulatory mechanisms of PD-L1 suggests that targeting DRG2, TRAPPC4, HIP1R, and CMTM6 could enhance the effectiveness of PD-1/PD-L1 blockade therapies. This strategy could create exciting new possibilities for cancer immunotherapy and improve patient outcomes.
PD-L1/PD-1信号轴是T细胞活性的关键调节因子，也是肿瘤逃避免疫监视的核心机制。抑制该通路可产生显著的抗肿瘤反应，使免疫检查点阻断（ICB）成为现代癌症治疗的重要组成部分。然而，许多高表达PD-L1的患者对PD-1/PD-L1阻断治疗无应答，这凸显了深入探究其耐药机制的必要性。近期研究发现，DRG2是抗PD-1治疗效果的关键调节因子。DRG2缺失虽能增强IFN-γ信号传导并提高PD-L1总体水平，但会破坏内体PD-L1的循环过程，导致其表面表达降低、PD-1相互作用受损，最终影响治疗效果。此外，TRAPPC4、HIP1R和CMTM6可通过阻止溶酶体降解来稳定PD-L1。研究表明，这些蛋白的缺失能增强机体对肿瘤的免疫应答。对PD-L1复杂调控机制的研究提示，靶向DRG2、TRAPPC4、HIP1R和CMTM6可能提升PD-1/PD-L1阻断疗法的疗效，为癌症免疫治疗开辟新前景并改善患者预后。
肿瘤(癌症)患者之家